Yaremchuk Michael J
Division of Plastic Surgery, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Mass. 02114, USA.
Plast Reconstr Surg. 2003 May;111(6):1818-27. doi: 10.1097/01.PRS.0000056866.80665.7A.
A retrospective review of clinical outcomes was performed to determine the clinical utility and morbidity associated with the use of porous polyethylene facial implants. Three hundred seventy implants were placed in 162 consecutive patients, in 178 operations performed in 11 years. The number of patients, the number of implants used, and the average follow-up period were categorized according to the cause of the deformity. The resultant distribution was as follows: acquired (tumor-related), 17 patients, 39 implants, and 30 months; congenital, eight patients, 31 implants, and 92 months; aesthetic, 39 patients, 97 implants, and 24 months; secondary posttraumatic, 48 patients, 139 implants, and 37 months; and acute trauma (internal orbit reconstruction), 50 patients, 64 implants, and 9 months. The distribution of implants according to location was as follows: frontal, 21; temporal, 30; internal orbit, 145; infraorbital rim, 28; malar, 58; paranasal, 29; nasal, 13; mandible, 24; and chin, 22. The combined average follow-up period per patient was 27 months (range, immediate postoperative period to 11 years). All implants were placed in the subperiosteal plane, and the majority were fixed with titanium screws. Antibiotics were administered perioperatively. No implants were extruded or migrated, formed clinically apparent capsules, or caused symptoms attributable to bioincompatibility. The overall reoperation rate was 10 percent (n = 16), which included operations to remove implants because of acute infections (2 percent, n = 3) or a late infection (1 percent, n = 1), to remove implants causing displeasing contours (2 percent, n = 3), and to improve contours (6 percent, n = 9). Porous polyethylene implants have biomaterial properties favorable for facial skeletal augmentation. Screw application of the implants to the skeleton allows precise predictable contouring, thus limiting the need for revisional surgical procedures.
进行了一项临床结果的回顾性研究,以确定使用多孔聚乙烯面部植入物的临床效用及相关发病率。在11年中进行的178次手术里,为162例连续患者植入了370枚植入物。根据畸形原因对患者数量、使用的植入物数量及平均随访时间进行了分类。结果分布如下:后天性(与肿瘤相关),17例患者,39枚植入物,随访30个月;先天性,8例患者,31枚植入物,随访92个月;美容性,39例患者,97枚植入物,随访24个月;继发性创伤后,48例患者,139枚植入物,随访37个月;以及急性创伤(眶内重建),50例患者,64枚植入物,随访9个月。植入物按位置分布如下:额部,21枚;颞部,30枚;眶内,145枚;眶下缘,28枚;颧骨,58枚;鼻旁,29枚;鼻部,13枚;下颌骨,24枚;以及颏部,22枚。每位患者的联合平均随访时间为27个月(范围,从术后即刻至11年)。所有植入物均置于骨膜下平面,且大多数用钛钉固定。围手术期使用抗生素。无植入物发生挤出或移位,未形成临床上明显的包膜,也未引起生物不相容性所致的症状。总体再手术率为10%(n = 16),其中包括因急性感染(2%,n = 3)或晚期感染(1%,n = 1)而取出植入物的手术、因植入物导致外形不佳而取出的手术(2%,n = 3)以及改善外形的手术(6%,n = 9)。多孔聚乙烯植入物具有有利于面部骨骼增大的生物材料特性。将植入物用螺钉固定于骨骼可实现精确可预测的塑形,从而减少翻修手术的需求。